Biobeat | September 07, 2022
Biobeat, a company focused on remote patient monitoring platforms with artificial intelligence analysis capability, has joined the American Heart Association Center for Health Technology & Innovation's (the Center) Innovators' Network. The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions.
The Innovators' Network is a consortium that connects entrepreneurs, providers, researchers and payers. Innovators' Network members also have access to the Association's digital guidelines, recommendations, and best-in-class science as they develop digital healthcare technologies. Members collaborate with the Center in different ways, including the building of models for clinical outcome studies, lowering the significant cost of developing those studies independently, helping connect the science to technology, and providing evidence that a digital platform improves healthcare outcomes – a key concern for providers and payers.
"The Center aims to advance the rapid, efficient, and effective development of healthcare technology," said Robert A. Harrington, M.D., FAHA, past president of the American Heart Association (2019-2020), volunteer chair of the American Heart Association's Health Tech Advisory Group for the Center and Arthur L. Bloomfield professor and chair department of medicine, Stanford University. "Joining the Innovators' Network gives members the opportunity to leverage the consortium and work toward broadening and deepening their engagement in this arena."
"Biobeat is excited to join the Innovators' Network. It will provide unique access to the Association's research and others innovating in this space, helping us to achieve our goals of improving cardiovascular health and helping health care providers."
Arik Eisenkraft, MD, VP Clinical and Regulation at Biobeat
Biobeat joins the Innovators' Network bringing with them the Biobeat solution, the first cuffless blood pressure measurement tool to receive FDA clearance. Biobeat leverages health-related artificial intelligence and med-tech capabilities to collect and analyze patient data with a suite of optical-based sensor monitors and machine learning data platforms focused on actionable insights.
Wireless sensors worn on the wrist or chest allow remote patient monitoring for blood pressure and multiple physiological parameters. Patient health data is viewed by participating medical staff via Biobeat's secure HIPAA and GDPR compliant cloud-based patient management platform. The platform includes an automated real-time early warning score system that incorporates advanced artificial intelligence algorithms to provide alerts on patient health status. These capabilities are centered on supporting medical teams in providing tailored patient care such as adjustment of therapeutics and early prevention of specific disease exacerbations. The company anticipates that compliance with easy-to-wear cuffless health sensor solutions will help healthcare professionals engage in timely, proactive care for hypertension patients.
FUTURE OF HEALTHCARE
Anumana, Inc. | July 14, 2022
Anumana, Inc., an AI-driven health technology company and portfolio company of nference, has launched a multi-year strategic collaboration with Novartis Pharmaceuticals Corporation (“Novartis”) to deploy a series of artificial intelligence powered software solutions that will detect hidden cardiovascular conditions. The collaboration will drive development and delivery of electrocardiogram (ECG) AI algorithms to help physicians accelerate detection and intervention for patients with previously undetected life-threatening heart disease. The ECG AI algorithm is still in development and not yet FDA authorized for commercial clinical use.
The collaboration will support Anumana’s efforts to implement AI-enabled diagnostic software that can detect signals from ECGs that humans cannot interpret. The collaboration will initially focus on cardiovascular diseases. Working with its expert partners from Mayo Clinic, Anumana will deploy novel solutions that use AI to analyze an ECG, a widely available, painless test that records the heart’s electrical signals to identify undiagnosed left ventricular dysfunction, or a weak heart pump, which can lead to heart failure. The AI will also screen for atherosclerotic cardiovascular disease, which can lead to heart attack and stroke. In addition, an evidence-based, digital point-of-care solution will be developed to guide in optimizing guideline-directed medical therapies with the aim to lower risk for potentially avoidable hospitalizations and cardiovascular death.
“Anumana technology is designed to help physicians identify patients who are at maximum risk of heart failure, long before they develop symptoms. Bringing together premier global organizations will allow us to expand access to best-in-class, AI-powered digital tools to benefit patients through earlier detection and intervention, when and where health care providers need it most.”
Murali Aravamudan, CEO of Anumana
“Many heart diseases develop for years before signs and symptoms appear, but the first event may be life threatening,” said Paul Friedman, M.D., Chair of the Department of Cardiovascular Medicine at Mayo Clinic and Chair of Anumana’s Mayo Clinic Board of Advisors. “AI enables us to uncover hidden signals our bodies transmit to detect otherwise occult heart diseases, potentially years before symptoms appear. This collaboration has the potential to transform the use of a ubiquitous inexpensive test, the ECG, with the aim of democratizing disease detection and helping medical care teams to proactively manage heart disease ahead of time and prevent some clinical events from ever happening.”
“Cardiovascular disease is a widespread and multifactorial disease and, in order to mitigate its impact, we must look beyond therapeutic innovation and reimagine how we approach cardiovascular care,” said Victor Bulto, President, Novartis Innovative Medicines US. "Novartis is proud to collaborate with Anumana on innovative and data-driven solutions to better predict the risk of life-threatening heart disease, further driving forward our commitment to improving patient experiences and population health outcomes in this patient population.”
The Mayo Clinic Cardiology team, led by Dr. Friedman, pioneered the application of AI in cardiology and developed several algorithms based on millions of ECGs, including a low ejection fraction algorithm that received FDA Breakthrough Device Designation in 2019 and Emergency Use Authorization for COVID-19 in 2020. Further validating the technology, a recent study presented by Mayo Clinic used a modified version of Anumana’s 12-lead ECG algorithm to detect left ventricular dysfunction with single-lead ECGs in smartwatches. These algorithms are licensed to Anumana for development of clinical solutions and have been validated by over 30 peer-reviewed publications, including a first of its kind prospective clinical impact study on low ventricular ejection fraction that was published in Nature Medicine in 2021. These software solutions are currently in development with each algorithm as a candidate for marketing authorization through an FDA De Novo request.
Anumana, an AI-driven health technology company and a portfolio company of nference and Mayo Clinic Platform, is harnessing industry-leading AI and translational science to decode the electrocardiogram as never before – as a deep predictive tool and biomarker of disease – empowering care providers to help patients early. Anumana algorithms have been developed, trained, and validated using clinical data from Mayo Clinic and are undergoing rigorous clinical trial validation. Anumana is developing AI-enabled ECG algorithms for real-world physician use, integrating point-of-care applications into existing workflows, thereby reducing costs and enhancing quality of life. Anumana’s AI-enabled tools can diagnose hidden conditions earlier than ever before. Anumana’s algorithms are investigational medical devices and have not yet received regulatory approval or clearance.
Advantage Healthcare Services and Spencer Health Solutions | September 26, 2022
Spencer Health Solutions a digital health company based in North Carolina’s Research Triangle Park, announced that Advantage Healthcare Services, a leading provider of mental health pharmacy support for the state of California, has joined its Certified Pharmacy Partner Network to offer enhanced, in-home patient services for one of its largest commercial pharmaceutical programs.
As part of the Spencer-Certified Pharmacy Partner Network, Advantage Health will work cooperatively with SHS, pharmaceutical manufacturers, payers, and healthcare systems on large-scale, post-approval monitoring sponsored by pharmaceutical companies that provide in-home support for patients living with severe and persistent behavioral health conditions.
“Our proactive approach to patient attention and care enables us to be with a patient during all aspects of their treatment and therapies. Participating in Spencer Health Solutions’ commercial pharmacy programs, and using the spencer® patient support platform, fits perfectly with our mission to work closely with a patient and their medical team to consult, observe, and intervene when the need arises for complete collaborative healthcare.”
Nevil Jhaveri, Chief Technology Officer at Advantage Healthcare Services
The spencer smart hub collects longitudinal insights from patients that can be leveraged to generate patient interventional support strategies. The smart hub is an FDA-certified Class 1 medical device that is easy to set up and use, only requiring the patient to plug it in and place a refill pack of medicines inside. The device connects to the Internet through an integrated cellular network or the user’s Wi-Fi network to quickly and securely
Alert patients to take their pre-packaged medications on a prescribed schedule
Dispense medications and document medication adherence.
Gain greater patient access with integrated, secure telehealth services within the platform
Automatically integrate data from in-home wearable, biometric devices.
“We feel fortunate to partner with Advantage and contribute to their long-standing reputation for thinking outside the box in support of their patients,” said Tom Rhoads, founder and CEO of Spencer Health Solutions. “Having spencer in patients’ homes will significantly improve health outcomes for this high-risk population that struggles with medication adherence and engagement.”
Spencer Health Solutions is exhibiting its spencer smart hub and pouch technology at the upcoming National Association of Specialty Pharmacists (NASP) 2022 Annual Meeting and Expo, and has been invited to present at the event’s Technology Day Innovation Lab on September 19th. Spencer Health Solutions invites NASP event attendees to join them for the unique one-day workshop, or to schedule a time for a personal, on-site demo.
About Advantage Healthcare Services
Advantage Healthcare Services’ core mission is to create solutions that support patients through the care continuum and aid in improving health outcomes. Based in California, Advantage specializes in crafting tailored solutions that bridge medication access and adherence impasses. With a primary focus of serving patients suffering from behavioral and mental health disorders, the company takes a consulting approach to developing sustainable solutions for the private practice sector, as well as for state- and county-funded programs. Through the utilization of an in-house data and analytics team, Advantage produces actionable reporting tools to identify at-risk patients, enabling caretakers to proactively intervene, improve health outcomes, and reduce rehospitalizations.
About Spencer Health Solutions
Spencer Health Solutions is a digital health technology provider dedicated to improving patient engagement and medication adherence for clinical trials and commercial pharmaceutical programs. Headquartered in North Carolina’s Research Triangle Park, Spencer Health Solutions’ award-winning spencer® smart hub provides near real-time monitoring of patients’ behaviors and Rx patterns that result in improved persistency, improved patient retention, and more positive health outcomes.